ReviewFrontiers in molecular biosciences2026
Gut microbiota-cancer crosstalk: emerging molecular targets for personalized cancer treatment- a comprehensive review.
Review in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains a major global health challenge, and growing evidence indicates that the gut microbiota plays an important role in cancer initiation, progression, metastasis, and response to treatment through complex interactions with host signaling, metabolism, and immunity. This comprehensive narrative review discusses the molecular mechanisms underlying gut microbiota-cancer crosstalk, with particular emphasis on dysbiosis, microbial metabolites, immune modulation, and microbiota-regulated oncogenic pathways, including TLR/NF-κB, Wnt/β-catenin, JAK/STAT, PI3K/Akt/mTOR, and Hippo-YAP signaling. The review also examines emerging molecular targets, including microbial extracellular vesicles, bacterial small RNAs, ferroptosis-related mechanisms, and microbiota-mitochondria interactions. In addition, current microbiota-targeted therapeutic strategies, such as fecal microbiota transplantation, engineered bacterial therapeutics, CRISPR-based microbiome engineering, and microbiome-informed approaches to precision oncology are discussed. Relevant peer-reviewed literature published primarily within the recent 5-year period was considered from major scientific databases and publisher platforms, including PubMed, Scopus, Web of Science, Springer, Elsevier, and MDPI. Overall, the available evidence suggests that gut microbiota represents an important component of the tumor ecosystem and may provide promising biomarkers and therapeutic targets. Integration of microbiome research with multi-omics and artificial intelligence may further support the development of personalized cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.